Medical treatment of freezing of gait

Movement Disorders

Volumn 23, Issue SUPPL. 2, 2008, Pages

  Giladi, Nir ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Dopamine agonist; Freezing of gait; Levodopa; Parkinson's disease; Treatment

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BOTULINUM TOXIN; CAFFEINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; METHYLPHENIDATE; MONOAMINE OXIDASE B INHIBITOR; NAXAGOLIDE; PERGOLIDE; PLACEBO; RASAGILINE; SELEGILINE; THREO 3,4 DIHYDROXYPHENYLSERINE;

CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALL RISK; FREEZING OF GAIT; GAIT DISORDER; HUMAN; LEG MUSCLE; MOTOR PERFORMANCE; MUSCLE CONTRACTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TURNING TASK; WALKING;

ANTI-DYSKINESIA AGENTS; DOPAMINE AGENTS; FREEZING REACTION, CATALEPTIC; GAIT; GAIT DISORDERS, NEUROLOGIC; HUMANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE;

EID: 52649164003     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21914     Document Type: Review

References (52)

1. Giladi N, Tal J, Meiron R, et al. Validation of the freezing of gait questionnaire (FOG-Q) for patients with Parkinson's disease. Mov Disord (in press).
2. Mizuno Y, Kondo T, Takubo H, Yokochi F. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease]. No To Shinkei 1996;48:467-472.
3. Ambani LM, Van Woert MH. Start hesitation - a side effect of long-term levodopa therapy. N Engl J Med 1973;288:1113-1115.
4. Schaafsma JD, Balash Y, Gurevich T, Bartels AL, Hausdortf JM, Giladi N. Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease. Eur J Neurol 2003;10:391-398.
5. Lee MS, Kim HS, Lyoo CH. "Off" gait freezing and temporal discrimination threshold in patients with Parkinson disease. Neurology 2005;64:670-674.
6. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005; 252 (Suppl 4):IV37-IV42.
7. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
8. Giladi N, McDermott MP, Fahn S, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56:1712-1721.
9. Bartels AL, Balash Y, Gurevich T, Schaafsma JD, Hausdorff JM, Giladi N. Relationship between freezing of gait (FOG) and other features of Parkinson's: FOG is not correlated with bradykinesia. J Clin Neurosci 2003;10:584-588.
10. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342:1484-1491.
11. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
12. Ahlskog JE, Muenter MD, Bailey PA, Stevens PM. Dopamine agonist treatment of fluctuating Parkinsonism. D-2 (controlled-release MK-458) vs. combined D-1 and D-2 (pergolide). Arch Neurol 1992;49:560-568.
13. Giladi N, Hausdorff JM. The role of mental function in the pathogenesis of freezing of gait in Parkinson's disease. J Neurol Sci 2006;248:173-176.
14. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of Parkinsonism. Ann Neurol 1998;44(3, Suppl 1):S160-S166.
15. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 2002;51:604-612.
16. Giladi N, Honigman S, Hocherman S. The effect of deprenyl treatment on directional and velocity control of arm movement in patients with early stages of Parkinson's disease. Clin Neuropharmacol 1999;22:54-59.
17. Zuniga C, Lester J, Cersosimo MG, Diaz S, Micheli FE. Treatment of primary progressive freezing of gait with high doses of selegiline. Clin Neuropharmacol 2006;29:20-21.
18. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:470-475.
19. Giladi N, Shabtai H, Simon ES, Biran S, Tal J, Korczyn AD. Construction of freezing of gait questionnaire for patients with Parkinsonism. Parkinsonism Relat Disord 2000;6:165-170.
20. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
21. Giladi N, Rascol O, Brooks E, et al. Rasageline treatment can improve freezing of gait in advanced Parkinson's disease: a prospective randomized, double blind placebo and entacapone controlled study. Mov Disord 2004;19 (Suppl 9):S191 (abstract).
22. Coria F, Cozar-Santiago MD. Rasageline defrosts gaits in a patient with primary progressive freezing gait. Mov Disord (in press).
23. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-1556.
24. Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006;21:1375-1379.
25. Giladi N, Treves TA, Simon ES, et al. Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 2001;108:53-61.
26. Macht M, Kaussner Y, Moller JC, et al. Predictors of freezing in Parkinson's disease: a survey of 6,620 patients. Mov Disord 2007; 22:953-956.
27. Kondo T. Drug intervention for freezing of gait resistant to dopaminergic therapy: a pilot study. Parkinsonism Relat Disord 2006;12 (Suppl 2):S63-S66.
28. Giladi N, Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson's disease. Mov Disord 1997;12:1085-1086.
29. Giladi N, Gurevich T, Shabtai H, Paleacu D, Simon ES. The effect of botulinum toxin injections to the calf muscles on freezing of gait in Parkinsonism: a pilot study. J Neurol 2001;248:572-576.
30. Nieuwboer A, Dom R, De Weerdt W, Desloovere K, Fieuws S, Broens-Kaucsik E. Abnormalities of the spatiotemporal characteristics of gait at the onset of freezing in Parkinson's disease. Mov Disord 2001;16:1066-1075.
31. Nieuwboer A, Dom R, De Weerdt W, Desloovere K, Janssens L, Stijn V. Electromyographic profiles of gait prior to onset of freezing episodes in patients with Parkinson's disease. Brain 2004;127 (Part 7):1650-1660.
32. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit 2004;10:CR282-CR284.
33. Wieler M, Camicioli R, Jones CA, Martin WR. Botulinum toxin injections do not improve freezing of gait in Parkinson disease. Neurology 2005;65:626-628.
34. Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study. Mov Disord 2007;22:880-883.
35. Narabayashi H, Yokochi F, Ogawa T, Igakura T. [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease]. No To Shinkei 1991; 43:263-268.
36. Narabayashi H, Kondo T, Yokochi F, Nagatsu T. Clinical effects Of L-threo-3,4-dihydroxyphenylserine in cases of Parkinsonism and pure akinesia. Adv Neurol 1987;45:593-602.
37. Quinn N, Perlmutter J, Marsden CD. Acute administration of DL-threo DOPS does not affect the freezing phenomenon in parkinsonian patients. Neurology 1984;34:149.
38. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE-trial. J Neurol Neurosurg Psychiatry 2007;78:134-140.
39. Yener GG, Kaya GC, Ozturk V, Akdal G. Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia. Ann Nucl Med 2005;19:607-609.
40. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37:457-470.
41. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-2037.
42. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004;55:766-773.
43. Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 2001;24:208-213.
44. Auriel E, Hausdorff JM, Herman T, Simon ES, Giladi N. Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clin Neuropharmacol 2006;29: 15-17.
45. Hausdorff JM, Schaafsma, JD, Balash Y, Bartels AL, Gurevich T, Giladi N. Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res 2003;149: 187-194.
46. Yogev G, Hausdorff JM, Giladi N. The role of executive function in gait (review). Mov Disord (in press).
47. Pollak L, Dobronevsky E, Prokhorov T, Bahunker S, Rabey JM. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neurol Transm (suppl) 20007;72: 145-148.
48. Nutt JG, Carter JH, Carlson NE. Efects of Methylphenidate on response to oral levodopa: a double-blind clinical trial. Arch Neurol 2007;64:319-323.
49. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. "Panic attacks" in Parkinson's disease - a long-term complication of levodopa therapy. Acta Neurol Scand 1993;87:14-18.
50. Lieberman A. Are freezing of gait (FOG) and panic related? J Neurol Sci 2006;248:219-222.
51. Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 2007;22:710-712.
52. Okuma Y. Freezing of gait in Parkinson's disease. J Neurol 2006; 253 (Suppl 7):vii27-vii32.